Biochemical correction of very long-chain acyl-coa dehydrogenase deficiency following adeno-associated virus gene therapy

Molecular Therapy

Volumn 17, Issue 3, 2009, Pages 425-429

  Merritt, J Lawrence ^a   Nguyen, Tien ^b   Daniels, Jan ^b   Matern, Dietrich ^b   Schowalter, David B ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; ACYLCARNITINE; PARVOVIRUS VECTOR;

ACETYL COENZYME A ACYLTRANSFERASE DEFICIENCY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; ENZYME DEFICIENCY; GENE EXPRESSION; GENE REPLACEMENT THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; MOUSE; NONHUMAN; PHENOTYPE; TISSUE DISTRIBUTION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; WESTERN BLOTTING;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 61649125586     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.295     Document Type: Article

References (35)

1. Rinaldo, P, Matern, D and Bennett, MJ (2002). Fatty acid oxidation disorders. Annu Rev Physiol 64: 477-502.
2. Schowalter, DB, Matern, D and Vockley, J (2005). In vitro correction of medium chain acyl CoA dehydrogenase deficiency with a recombinant adenoviral vector. Mol Genet Metab 85: 88-95.
3. Conlon, TJ, Walter, G, Owen, R, Cossette, T, Erger, K, Gutierrez, G et al. (2006). Systemic correction of a fatty acid oxidation defect by intramuscular injection of a recombinant adeno-associated virus vector. Hum Gene Ther 17: 71-80.
4. Beattie, SG, Goetzman, E, Tang, Q, Conlon, T, Campbell-Thompson, M, Matern, D et al. (2008). Recombinant adeno-associated virus-mediated gene delivery of long chain acyl coenzyme A dehydrogenase (LCAD) into LCAD-deficient mice. J Gene Med 10: 1113-1123.
5. Aoyama, T, Souri, M, Ushikubo, S, Kamijo, T, Yamaguchi, S, Kelley, RI et al. (1995). Purification of human very-long-chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients. J Clin Invest 95: 2465-2473.
6. Strauss, AW, Powell, CK, Hale, DE, Anderson, MM, Ahuja, A, Brackett, JC et al. (1995). Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. Proc Natl Acad Sci USA 92: 10496-10500.
7. Zytkovicz, TH, Fitzgerald, EF, Marsden, D, Larson, CA, Shih, VE, Johnson, DM et al. (2001). Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: A two-year summary from the New England Newborn Screening Program. Clin Chem 47: 1945-1955.
8. Wilcken, B, Wiley, V, Hammond, J and Carpenter, K (2003). Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 348: 2304-2312.
9. Chace, DH, Kalas, TA and Naylor, EW (2002). The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism. Annu Rev Genomics Hum Genet 3: 17-45.
10. Spiekerkoetter, U, Sun, B, Zytkovicz, T, Wanders, R, Strauss, AW and Wendel, U (2003). MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency. J Pediatr 143: 335-342.
11. Vianey-Saban, C, Divry, P, Brivet, M, Nada, M, Zabot, MT, Mathieu, M et al. (1998). Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: Clinical characteristics and diagnostic considerations in 30 patients. Clin Chim Acta 269: 43-62.
12. Hoffman, JD, Steiner, RD, Paradise, L, Harding, CO, Ding, L, Strauss, AW et al. (2006). Rhabdomyolysis in the military: Recognizing late-onset very long-chain acyl Co-A dehydrogenase deficiency. Mil Med 171: 657-658.
13. Bertrand, C, Largilliere, C, Zabot, MT, Mathieu, M and Vianey-Saban, C (1993). Very long chain acyl-CoA dehydrogenase deficiency: identification of a new inborn error of mitochondrial fatty acid oxidation in fibroblasts. Biochim Biophys Acta 1180: 327-329.
14. Bonnet, D, de Lonlay, P, Gautier, I, Rustin, P, Rotig, A, Kachaner, J et al. (1998). Efficiency of metabolic screening in childhood cardiomyopathies. Eur Heart J 19: 790-793.
15. Bonnet, D, Martin, D, Pascale De, L, Villain, E, Jouvet, P, Rabier, D et al. (1999). Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation 100: 2248-2253.
16. de Lonlay-Debeney, P, Fournet, JC and Bonnet, D (1998). Fatty acid β-oxidation deficiency masquerading as fulminant myocarditis. Int J Cardiol 65: 287-289.
17. Kluge, S, Kuhnelt, P, Block, A, Merkel, M, Gocht, A, Lukacs, Z et al. (2003). A young woman with persistent hypoglycemia, rhabdomyolysis, and coma: Recognizing fatty acid oxidation defects in adults. Crit Care Med 31: 1273-1276.
18. Chace, DH, DiPerna, JC, Mitchell, BL, Sgroi, B, Hofman, LF and Naylor, EW (2001). Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death. Clin Chem 47: 1166-1182.
19. Vockley, J and Whiteman, DA (2002). Defects of mitochondrial β-oxidation: A growing group of disorders. Neuromuscul Disord 12: 235-246.
20. Solis, JO and Singh, RH (2002). Management of fatty acid oxidation disorders: A survey of current treatment strategies. J Am Diet Assoc 102: 1800-1803.
21. Straussberg, R, Harel, L, Varsano, I, Elpeleg, ON, Shamir, R and Amir, J (1997). Recurrent myoglobinuria as a presenting manifestation of very long chain acyl coenzyme A dehydrogenase deficiency. Pediatrics 99: 894-896.
22. Xiao, W, Berta, SC, Lu, MM, Moscioni, AD, Tazelaar, J and Wilson, JM (1998). Adeno-associated virus as a vector for liver-directed gene therapy. J Virol 72: 10222-10226.
23. Grimm, D, Zhou, S, Nakai, H, Thomas, CE, Storm, TA, Fuess, S et al. (2003). Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 102: 2412-2419.
24. Koeberl, DD, Sun, BD, Damodaran, TV, Brown, T, Millington, DS, Benjamin, DK Jr et al. (2006). Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia. Gene Ther 13: 1281-1289.
25. Moscioni, D, Morizono, H, McCarter, RJ, Stern, A, Cabrera-Luque, J, Hoang, A et al. (2006). Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors. Mol Ther 14: 25-33.
26. Gao, G, Vandenberghe, LH and Wilson, JM (2005). New recombinant serotypes of AAV vectors. Curr Gene Ther 5: 285-297.
27. Wang, Z, Zhu, T, Qiao, C, Zhou, L, Wang, B, Zhang, J et al. (2005). Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 23: 321-328.
28. Merritt, JL 2nd, Matern, D, Vockley, J, Daniels, J, Nguyen, TV and Schowalter, DB. (2006). In vitro characterization and in vivo expression of human very-long chain acyl-CoA dehydrogenase. Mol Genet Metab 88: 351-358.
29. Cox, KB, Hamm, DA, Millington, DS, Matern, D, Vockley, J, Rinaldo, P et al. (2001). Gestational, pathologic and biochemical differences between very long-chain acyl-CoA dehydrogenase deficiency and long-chain acyl-CoA dehydrogenase deficiency in the mouse. Hum Mol Genet 10: 2069-2077.
30. Souri, M, Aoyama, T, Hoganson, G and Hashimoto, T (1998). Very-long-chain acyl-CoA dehydrogenase subunit assembles to the dimer form on mitochondrial inner membrane. FEBS Lett 426: 187-190.
31. Kay, MA, Baley, P, Rothenberg, S, Leland, F, Fleming, L, Ponder, KP et al. (1992). Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc Natl Acad Sci USA 89: 89-93.
32. Palomeque, J, Chemaly, ER, Colosi, P, Wellman, JA, Zhou, S, Del Monte, F et al. (2007). Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther 14: 989-997.
33. Zaiss, AK and Muruve, DA (2008). Immunity to adeno-associated virus vectors in animals and humans: A continued challenge. Gene Ther 15: 808-816.
34. Franco, LM, Sun, B, Yang, X, Bird, A, Zhang, H, Schneider, A et al. (2005). Evasion of immune responses to introduced human acid α-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther 12: 876-884.
35. 2+ handling in very-long-chain acyl-CoA dehydrogenase null mice. Am J Physiol Heart Circ Physiol 292: H2202-H2211.